AI-designed drug candidate, Rentosertib (ISM001-055) received IND clearance

Insilico Medicine recently announced a major milestone for their AI-designed drug candidate, Rentosertib (ISM001-055).

Breakthrough in AI Drug Discovery
World First: This marks the first time an AI-driven drug candidate will enter a direct-to-lung clinical trial.

AI-Powered: Both the novel target and the molecule structure were identified and developed using Insilico’s generative AI platform, Pharma.AI.
Proven Pipeline: This is the 13th program from Insilico’s Medicine AI-driven pipeline to receive IND (Investigational New Drug) clearance.

Targeted Treatment for Lung Health
Precision Delivery: The inhalation solution is designed to deliver medicine directly to the lungs.

Enhanced Efficacy: Direct delivery allows for a rapid onset of action and high local bioavailability at lower doses.

Reduced Side Effects: By targeting the lungs specifically, the treatment reduces systemic exposure, which can minimize side effects throughout the rest of the body.

Clinical Progress
Building on Success: This new inhalation study follows positive Phase IIa results for the oral version of Rentosertib in treating Idiopathic Pulmonary Fibrosis (IPF).

Next Steps: A Phase I study will now evaluate the safety, tolerability, and pharmacokinetic profile of the inhalation solution in healthy volunteers.
Read more via https://insilico.com/news/pdmncgky51-insilicos-rentosertib-inhalation-solutio